Put companies on watchlist
SYNLAB AG
ISIN: DE000A2TSL71
WKN: A2TSL7
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

SYNLAB AG · ISIN: DE000A2TSL71 · EQS - adhoc news (77 News)
Country: Germany · Primary market: Germany · EQS NID: 1552999
06 February 2023 08:36PM

SYNLAB AG: SYNLAB revises FY 2023 guidance from lower COVID-19 testing volumes


EQS-Ad-hoc: SYNLAB AG / Key word(s): Change in Forecast
SYNLAB AG: SYNLAB revises FY 2023 guidance from lower COVID-19 testing volumes

06-Feb-2023 / 20:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


SYNLAB AG (SYNLAB, FSE: SYAB) is experiencing a reduced level of COVID-19 testing volume and dropping COVID-19 PCR prices in some of its key markets in January 2023. This leads SYNLAB to update its FY 2023 guidance despite anticipated continued growing underlying business and the focus to recover pre-pandemic productivity.
For 2023, SYNLAB now expects revenues to be around €2.7 billion (previously around €3.0 billion).
Furthermore, SYNLAB expects the adjusted EBITDA margin to be in a range of 16-18% (previously: at 18-20%). The adjusted EBITDA margin ranges-in the following factors: 1) the reduction of the COVID-19 testing volume and price, 2) the dilutive impact on the margin of setting up Direct to Consumer (D2C) activities, 3) general inflation risks, 4) a doubling of benefits from the SALIX programme in 2023 compared to prior years from productivity initiatives, and 5) lower M&A contribution.
SYNLAB will implement a temporary reduction of M&A spent in 2023 to around €100 million (as compared to the previous expectation of €200 million) to focus the business on reaching the same productivity level as before the pandemic outbreak.
SYNLAB continues to expect an underlying organic growth (excluding COVID-19 testing) at ~4%, driven by development of volumes and price increases within the core business.
For FY 2022, revenue is expected to be around €3.25 billion, above the previously guided amount of €3.2 billion with an adjusted EBITDA margin expected to be around 23% impacted by Q4 2022 one-off costs primarily from COVID-19 business.

06-Feb-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SYNLAB AG
Moosacher Straße 88
80809 Munich
Germany
Phone: +49 1701183753
E-mail: ir@synlab.com
Internet: www.synlab.com/
ISIN: DE000A2TSL71
WKN: A2TSL7
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1552999

 
End of Announcement EQS News Service

1552999  06-Feb-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1552999&application_name=news&site_id=boersengefluester_html
Visual performance / price development - SYNLAB AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.